Cutting-edge QA solutions, advanced treatment planning, intelligent software and new MR-linac data highlight depth and breadth of Elekta’s transformative oncology portfolio
NASHVILLE US — Thursday, July 26, 2018
At the 60th American Association of Physicists in Medicine (AAPM) Annual Meeting & Exhibition July 29 - August 2 in Nashville, Elekta will feature advanced quality assurance (QA) and treatment planning solutions that simplify the delivery of complex therapeutic treatment techniques, increasing accuracy, efficiency and confidence.
As the complexity of radiation therapy increases, the need to achieve stringent safety, efficacy and efficiency requirements places additional demands on clinics. With robust patient, machine and departmental solutions, Elekta helps clinics strengthen their QA portfolios with standardized, streamlined and automated QA procedures that assure these requirements are met for every patient and every treatment session.
Elekta QA demonstrations will include:
- AQUA, a comprehensive quality management solution that coordinates and centralizes all machine QA tests helping to manage the complexity of these testing requirements.
- iViewDose software, an EPID-based intra-fraction, in vivo patient dosimetry solution that offers an essential safety check during radiation therapy.
- End-to-end stereotactic quality assurance services, a solution using in vivo PseudoPatient™ technology that enables clinics to accelerate implementation of their stereotactic programs and optimize treatment strategies and protocols. Elekta has signed a memorandum of understanding with RTsafe to provide cancer centers an elegant QA solution by elevating confidence in the end-to-end accuracy of stereotactic systems and creating wider access to advanced stereotactic treatments.
Visitors to Elekta booth #301 also will have an opportunity to learn about treatment planning and software solutions, including:
- Monaco® , an advanced treatment planning system that powers more efficient high definition planning with true Monte Carlo accuracy and advanced multicriteria optimization. Customers can also preview our new Monaco community, a digital peer-to-peer platform that allows customers to share advanced applications, protocols and best practices.
- MOSAIQ® with Watson for Oncology unites cancer care and artificial intelligence pioneers Elekta and IBM Watson Health to offer Watson for Oncology with Elekta’s cancer care solutions. MOSAIQ enables value-based practice optimization and supports clinical decisions that can help outsmart cancer by transforming big data into personalized, precision approaches to managing cancer therapy.
- Leksell GammaPlan®, an integrated treatment planning and management software for Gamma Knife radiosurgery, including Leksell Gamma Knife® Icon™.
- Oncentra® Brachy, a comprehensive brachytherapy treatment planning software that enables efficient treatment delivery workflows and optimal dose distribution.
MR-linac abstracts add to growing body of data
Elekta and its clinical collaborators will present 31 abstracts supporting the technical applications of its Elekta MR-linac, which received CE mark as Elekta Unity in June 2018 and enables magnetic resonance radiation therapy (MR/RT), an innovative and personalized application of radiation therapy to the treatment of cancer.
Abstracts presented at the conference include:
- Radiobiological Advantages of Motion Tracking for Liver, Pancreas, and Kidney SBRT Tumors in a MR-Linac (Tuesday, July 31, 1:45 – 3:45 p.m.) – Demonstrates the potential benefits of using the MR-linac tracking system to reduce radiation exposure of normal tissue and organs at risk, especially the kidney, bowels and duodenum.
- Implementing Retrospective Four-Dimensional Magnetic Resonance Imaging (4D-MRI) On An MR-Guided Linear Accelerator (MR-Linac): A Feasibility Study (Wednesday, August 1, 10:15 a.m. – 12:15 p.m.) – Describes the successful implementation of a 4D MRI technique on the MR-linac. This technique is a promising tool for improving the visualization and delineation of tumors that move during the course of a treatment session.
- Potential Dose Escalation for Pancreas SBRT Patients as a Result of Simulated Tumor Tracking and Margin Reduction in a MR-Linac (Tuesday, July 31, 3:45 – 4:15 p.m.) – Demonstrates the potential benefit of using the MR-linac tracking system to escalate the dose in patients receiving stereotactic body radiation therapy (SBRT) for the treatment of pancreatic cancer.
For real-time updates from the AAPM show floor, our educational events and annual Physics User Meeting, follow the Elekta Twitter handle, @Elekta. To learn more about Elekta at AAPM, visit www.elekta.com/AAPM.
Elekta’s MR-linac has CE mark but is not available for commercial distribution or sale in the U.S.
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com